https://www.selleckchem.com/products/m4076.html
03 [p0.0001] for FACT M and 5.28 [p=0.0042] for EORTC QLQ-C3, indicative of a meaningful change in patient's status. Furthermore, a delay in the deterioration of QoL was observed in non-hospitalised patients compared to hospitalised patients (hazard ratio [95% CI] 1.16 [0.80; 1.68] for EORTC QLQ-C30 and 1.27 [0.81; 1.99] for FACT-M) and a risk reduction of 10% deterioration, favoured the combination in both groups. The improved efficacy of encorafenib plus binimetinib compared to vemurafenib, translates into a positive impact on the
Gefällt mir
Kommentar
Teilen
